Considering that anti-CTLA-4-treated melanoma patients rich in Bacteroidetes harness a lower risk for colitis mediated by the Tregs differentiation process, efforts to explore whether the anti-PD1/PD-L1 related toxicity could also be ameliorated in a bacteria-dependent manner are currently on the way (68). Here, PDCD1 is linked to melanoma.